Polycystic ovary syndrome: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• GLP-1 5
• PI3K 0
• AKT 0
• IL-6 0
• AMPK 0
• mTOR 0
• TNF 1
• PPAR 0
• NLRP3 0
• SIRT1 0
• NRF2 0
• STAT3 0
• TLR4 0
• AR 0
• TP53 0
• VEGF 0
• MAPK 0
• COX-2 0
• ERK 0
• ESR1 0
• IL-1 0
• BCL-2 0
• DPP-4 0
• GIP 0
• GPX4 0
• HMGB1 0
• JAK 0
• PINK1 0
• PTEN 0
• BDNF 0
• BRD4 0
• CD40 0
• EGFR 0
• IGF1R 0
• MMP-9 0
• PCSK9 0
• SGLT2 0
• STING 0
• STK11 0
• TERT 0
• BRCA1 0
• CTNNB1 0
• FTO 0
• HDAC 0
• HSP90 0
• IL-17 0
• JNK 0
• KIT 0
• METTL3 0
• NF1 0
• PARP 0
• PD-1 0
• PD-L1 0
• PDE4 0
• PKM2 0
• PNPLA3 1
• SHP2 0
• SOD1 0
• TREM2 0
• YAP 0

2+ intézményből 2, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R61

  Toll-Like Receptor 4 Antagonism for Infertility Management in Polycystic Ovary Syndrome

  University of California-Irvine· Irvine, Egyesült Államok· 435 691 USD awarded in fiscal year 2026· until 2028. jún.

• NIH OD · OT2

  Computational Modeling of Female Hormone Homeostasis and Drug Responses

  Henry Ford Health + Michigan State University Health Sciences· East Lansing, Egyesült Államok· 4 587 853 USD awarded in fiscal year 2026· until 2027. szept.

• NIH NIA · R01

  Reproductive events, menopause and biological aging among Latina women

  Emory University· Atlanta, Egyesült Államok· 720 040 USD awarded in fiscal year 2026· until 2031. ápr.

• NIH NICHD · R01

  Mechanisms and Therapeutic Potential of MKRN3 in the Neuroendocrine Regulation of Puberty and Reproduction

  Boston Children's Hospital· Boston, Egyesült Államok· 692 296 USD awarded in fiscal year 2026· until 2031. máj.

• NIH NICHD · R01

  Metformin for gestational diabetes: assessing risk of long-term childhood outcomes

  Rutgers Biomedical and Health Sciences· Newark, Egyesült Államok· 718 484 USD awarded in fiscal year 2026· until 2031. jún.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Elucidating the role of maternal nutrient stores in the metabolism of the preimplantation embryo (MaterMeta)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Cell type-specific endometrial dysfunctions across the menstrual cycle and their potential for drug interventions in polycystic ovary syndrome (POTRET)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 236 340 EUR· until 2028. júl.

• European Commission (Horizon 2020) · RIA

  PCOS IN ADOLESCENT GIRLS AND YOUNG WOMEN: TOWARD A TREATMENT GUIDED BY PATHOPHYSIOLOGY (SPIOMET4HEALTH)

  Fundacio Privada Per A la Recerca I la Docencia Sant Joan de Deu· Esplugues De Llobregat, Spanyolország· EU contribution 6 366 149 EUR· until 2026. dec.· 9 countries

8 of 74 running projects, newest first. Listed amounts together: 37,7 M USD + 6,9 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

  NCT07169136· Nemours Children's Clinic· Forrás

• Efficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS

  NCT07616037· Shanghai Zhongshan Hospital· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 9
• Organoids 4
• Mendelian Randomization Analysis 23
• CRISPR-Cas Systems 1
• Gene Expression Profiling 19
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Proteomics 13
• Metabolomics 22
• Mass Spectrometry 4
• Flow Cytometry 3
• Immunohistochemistry 6
• Magnetic Resonance Imaging 9
• Machine Learning 24
• Deep Learning 6
• Cohort Studies 75
• Genome-Wide Association Study 35

• Redefining Polycystic Ovary Syndrome: New Phenotypic Classifications and Implications.

  Endocrinol Metab Clin North Am, 2026. szept.

• Single-cell expression quantitative trait locus Mendelian randomization reveals immune cell-specific causal regulatory networks and actionable targets in polycystic ovary syndrome.

  Sci Prog, 2026. szept.

• Identification of CA2 as a potential candidate gene involved in the therapeutic effect of Huatan Huoxue decoction on polycystic ovary syndrome: An integrated study of network pharmacology, Mendelian randomization, and experimental validation.

  J Food Drug Anal, 2026. szept.

• Shared genetic architecture and cellular convergence between female reproductive disorders and pulmonary function: a genome-wide cross-trait analysis.

  Funct Integr Genomics, 2026. szept.

• Autoimmune disease influence on polycystic ovary syndrome: Insights from Mendelian randomization and multi-omics analysis.

  Adv Clin Exp Med, 2026. szept.

• Integrative Multi-omics Analysis for Prioritization of Candidate Genes in Polycystic Ovary Syndrome.

  FASEB J, 2026. aug.

• Mapping the causal landscape of polycystic ovary syndrome: A systematic Mendelian randomization evidence synthesis and the MR-PCOS atlas platform.

  Medicine (Baltimore), 2026. aug.

• Female-specific metabolic genetic liability reveals a separable metabolic dimension of polycystic ovary syndrome.

  Mol Cell Endocrinol, 2026. júl.

• Multitarget interactions of bisphenol A in polycystic ovary syndrome: evidence from integrated network toxicology, mendelian randomization, and molecular docking.

  F S Sci, 2026. júl.

• Gene prioritization across ancestries uncovers distinct molecular pathophysiology and therapeutic landscape in polycystic ovary syndrome.

  NPJ Syst Biol Appl, 2026. jún.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.